Placeholder Banner

BIO Elects New Board Directors and Re-Elects Section Governing Board Chairs

June 14, 2022
Media Contact
Karen Batra
202.449.6382

The Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Executive Committee directors for the 2022-2023 term.

BIO’s Board elections took place Monday, June 13 during the 2022 BIO International Convention hosted by BIO in San Diego, June 13-16, 2022.

“On behalf of our entire BIO organization, I want to congratulate our incoming Board directors and section leaders,” said Dr. Michelle McMurry-Heath, President & CEO of BIO. “This is a critical time for our industry. Our BIO Board – especially one as diverse and multi-faceted as this one – will help drive policies that keeps pace with innovation’s promise to cure disease, nourish society, and protect our planet.”

BIO’s Executive Committee directors for the 2022-2023 term are:

  • Paul Hastings, Nkarta Therapeutics – Board Chair/Health Section Chair
  • Elizabeth Lewis, Takeda Pharmaceuticals – Board Associate Vice Chair & Secretary
  • Bradford Zakes, Ceravast Medical – BIO Board Treasurer
  • Ted Love, Global Blood Therapeutics – Health Section Vice Chair
  • Sylvia Wulf, AquaBounty Technologies – Agriculture & Environment Section Chair
  • John Crowley, Amicus Therapeutics – Emerging Companies Section Chair
  • Jeremy Levin, Ovid Therapeutics – Immediate Past Chair
  • Erika Smith, ReNetX BIO – Emerging Companies Section Vice Chair
  • Anna Rath, Vestaron
  • Doug Doerfler, MaxCyte
  • Stuart Arbuckle, Vertex Pharmaceuticals
  • Christi Shaw, Kite, A Gilead Company
  • Bill Sibold, Genzyme, A Sanofi Company
  • Fritz Bittenbender, Genentech Roche
  • Chris Boerner, Bristol Myers Squibb
  • Eric Dube, Travere Therapeutics
  • Sue Washer, Applied Genetic Technologies Corporation (AGTC)
  • Aamir Malik, Pfizer
  • Jannie Oosthuizen, Merck
  • Victor Bulto, Novartis Pharmaceuticals
  • Bill Newell, Sutro BioPharma

Additional directors who were confirmed as the Executive Advisory Board (EAB) to the Executive Committee:

  • Ron Cohen, Acorda Therapeutics
  • Rachel King, former BIO Board Chair
  • John Maraganore, former BIO Board Chair
  • Richard Pops, Alkermes

Newly Elected to the BIO Health Section Governing Board (2022-2025 Term):

  • Jannie Oosthuizen, Merck

Newly Elected to the BIO Emerging Companies Section Governing Board (2022-2023 Term):

  • Pablo Cagnoni, Rubius Therapeutics
  • Kaye Foster, The Boston Consulting Group
  • Mike Huckman, Real Chemistry
  • Elizabeth Jeffords, Iolyx Therapeutics
  • Sheila Mikhail, Asklepios BioPharmaceutical

Newly Elected to the BIO Agriculture and Environment Section Governing Board (2022-2024 Term):

  • Angela Ailloni, Ginkgo Bioworks
  • Rocco Morelli, Recombinetics

Discover More
The Biotechnology Innovation Organization (BIO) released an updated report produced in partnership with the International Council of Biotechnology Associations (ICBA) that highlights biotechnology’s role in meeting the United Nations’ 17 Sustainable…
Today, the Biotechnology Innovation Organization released a poll that shows voters overwhelmingly support the ORPHAN Cures Act, a recently introduced bill that would incentivize rare disease drug development.   The…
The next farm bill offers opportunities to invest in long-term food security, climate resiliency and growing the nation’s burgeoning bioeconomy, according to the Biotechnology Innovation Organization, which has submitted recommendations to the House…